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ERp57 is a member of the protein disulfide isomerase
(PDI) family that is located in the endoplasmic reticu-
lum (ER) and characterized by its specificity for glyco-
proteins. Substrate selection by ERp57 is dependent
upon its formation of discrete complexes with two ER
resident lectins, soluble calreticulin and membrane-
bound calnexin. It is these two lectins that directly as-
sociate with glycoproteins bearing correctly trimmed
oligosaccharide side chains. Thus, ERp57 is presented
with a preselected set of substrates upon which it can
act, and the specific binding of calreticulin and calnexin
to ERp57 is pivotal to the functions of the resulting
complexes. To gain further insights into the formation
of these ERp57-ER lectin complexes, we have investi-
gated the regions of ERp57 that are specifically required
for its binding to calreticulin. Using a quantitative pull-
down assay to investigate the binding of ERp57/PDI chi-
meras to calreticulin, we define the b and b domains of
ERp57 as the minimal elements that are sufficient for
complex formation. This analysis further identifies a
novel role for the distinctive C-terminal extension of
ERp57 in reconstituting complex formation to wild type
levels. Using our understanding of substrate binding to
the b domain of PDI as a paradigm, we show that alter-
ations to specific residues in the b domain of ERp57
dramatically reduce or completely abolish its binding to
calreticulin. On the basis of these data, we propose a
model where the region of ERp57 equivalent to the pri-
mary substrate binding site of archetypal PDI is occu-
pied by calreticulin and suggest that the ER lectins act
as adaptor molecules that define the substrate specific-
ity of ERp57.
The ER1 contains a number of molecular chaperones and
folding factors that facilitate the folding and assembly of newly
synthesized polypeptides as they are translocated across the
ER membrane and into its lumen. Among these, a set of glyco-
protein-specific components have been identified and found to
be dependent upon the covalent attachment of N-linked oligo-
saccharides to nascent polypeptides (1, 2). This recruitment
process is tightly regulated by the glucose trimming of the
N-linked glycans such that the monoglucosylated form of the
oligosaccharide binds to two homologous ER lectins, calnexin
and calreticulin, that are pivotal to the chaperone-mediated
folding of glycoproteins (1, 2). There is evidence that the inte-
gral membrane protein calnexin, and the soluble luminal pro-
tein calreticulin, can act as bona fide molecular chaperones,
and hence might influence protein folding directly (3, 4). How-
ever, a primary function of calnexin and calreticulin is to bring
newly synthesized glycoproteins together with the protein di-
sulfide isomerase (PDI)-like protein ERp57, and these ER lec-
tin-ERp57 complexes significantly promote native disulfide
bond formation in their glycoprotein substrates (5, 6). In prac-
tice, ERp57 has been shown to form stable complexes with both
calnexin and calreticulin, and these complexes can be readily
detected using an in vitro cross-linking assay (7).
High resolution structures for substantial segments of calre-
ticulin and calnexin are available (8–10). Further studies show
that ERp57 binds to the tip of the P-domain of calreticulin (11,
12), an extended hairpin fold that protrudes from the compact
globular domain containing the lectin activity and that is con-
served in calnexin (10). A second, zinc-dependent interaction of
ERp57 with the globular domains of these ER lectins can also
be detected in vitro (12). In contrast, the one or more regions of
ERp57 that enable it to assemble specifically with calnexin and
calreticulin are unclear (cf. Ref. 7).
All of the members of the PDI family are characterized by a
modular structure, and both PDI and ERp57 have the same
basic domain organization of a, b, b, a, and c where the a and
a domains contain the thioredoxin-like motif Cys-Xaa-Xaa-Cys
(see Ref. 13). For PDI, simple thiol-disulfide chemistry only
requires the a or a domains, and simple isomerization requires
one of these active domains in combination with the b domain
(14, 15). However, complex isomerization requires all four PDI
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domains (abba), but not the C-terminal region (14, 15). The b
domain was found to be essential for PDI-protein substrate
interactions and is sufficient for the binding of small peptides,
although other domains contributed to the association of PDI
with large peptides and partially unfolded proteins (16–18).
Hence, the b domain of PDI appears to be its principle peptide
binding site, although other domains may be required for in-
teractions with larger substrates. The conserved modular
structure of PDI and ERp57 has been exploited to generate
chimeras that have then been used to define the one or more
regions of PDI that facilitate specific interactions with other
ER proteins to generate protein complexes with defined func-
tions. Using this approach it was found that both the b and a
domains of PDI are the minimum requirement for it to function
as a subunit of collagen prolyl 4-hydroxylase and that the
inclusion of the b domain enhances this activity significantly
(19).
We have previously shown that ERp57 associates specifically
with the two ER lectins, calnexin and calreticulin, whereas
archetypal PDI does not (7). To establish the molecular basis
for the specific assembly of ERp57 with calnexin and calreti-
culin, we have exploited chimeras derived from the two related
proteins to map the domains of ERp57 that mediate its binding
to the ER lectins. Using a newly established pull-down assay,
we find that the principal binding site for calreticulin lies
within the region defined by the b and b domains of ERp57 and
show that its distinct C-terminal region enhances ERp57 bind-
ing. To more closely define the binding of calreticulin to ERp57,
we have exploited our knowledge of substrate binding to PDI.
Using previously characterized point mutants of the PDI b
domain as a starting point (18), we show that the alteration of
equivalent residues in the ERp57 b domain can completely
abolish its binding to calreticulin while still allowing the pro-
tein to attain a structure comparable to that of the wild type
protein. On the basis of these data we propose that regions of
ERp57 equivalent to the substrate binding site of PDI are
occupied by calnexin or calreticulin, and these lectins act as
adaptors that specifically recruit glycoprotein substrates to the
ERp57-ER lectin chaperone complexes.
EXPERIMENTAL PROCEDURES
Materials—Bismaleimidohexane (BMH) was purchased from Pierce
and Warriner (Chester, UK), restriction endonucleases were from
New England Biolabs (Herts, UK), and RNA polymerase, transcrip-
tion reagents, and rabbit reticulocyte lysate were from Promega
(Southampton, UK). Easytag L-[35S]methionine was obtained from
PerkinElmer Life Sciences (Stevenage, UK), whereas all other chemi-
cals were from BDH/Merck (Poole, UK) and Sigma (Poole, UK). The
rabbit antiserum specific for the C-terminal region of human ERp57
FIG. 1. Outline of the origins of the ERp57/PDI chimeras used
in this study. Domains (as defined in Ref. 13) derived from ERp57 are
stippled, whereas those from PDI are in white. The number and approx-
imate location of each cysteine residue present in the mature (signal
sequence cleaved) polypeptides is indicated. The various derivatives
have the ER signal sequence from the N-terminal polypeptide and then
the following residues (numbering refers to full-length human ERp57
and PDI sequences, including their respective ER signal sequences):
ERp57  Ser25-Leu505, ERp57C  Ser25-Ile490, chimera 2  ERp57
Ser25-Gly242 and PDI Leu236-Leu508, chimera 3  ERp57 Ser25-Gly376
and PDI Pro368-Leu508, chimera 4  PDI Asp18-Gly134 and ERp57
Pro134-Leu505, chimera 5  PDI Asp18-Gln367 and ERp57 Pro377-Val489,
chimera 6 same as chimera 5 plus the sequence AVKDEL (cf. Ref. 19).
Note that mature ERp57 starts at Ser25 and PDI at Asp18.
FIG. 2. ERp57 binds specifically to immobilized calreticulin.
ERp57 (A), ERp57ss (B), and PDI (C) were synthesized as 35S-labeled
polypeptides in reticulocyte lysate and then mixed with NeutrAvidin
beads alone (A–C, lane 2), NeutrAvidin beads loaded with biotin-tagged
insulin (A–C, lane 3), or NeutrAvidin beads loaded with biotin-tagged
calreticulin (A–C, lane 4). In the case of ERp57, additional incubations
using NeutrAvidin beads loaded with biotin-tagged calreticulin and
preincubated with either “native” or “scrambled” RNase A (A, lanes 5
and 6, respectively) were included, as were samples where His-tagged
calreticulin or recombinant PDI were added in conjunction with radio-
labeled ERp57 (A, lanes 7 and 8, respectively). The percentage of the
total radiolabeled input that was recovered bound to the beads was
calculated by quantitative phosphorimaging using an equal fraction of
the translation products for comparison (A–C, lane 1). Levels of radio-
labeled material that are significantly above background are indicated
by a gray arrowhead (cf. D). D, the basic binding assay was repeated
twice and the average value and standard error for the proportion of
material recovered with beads alone (checkerboard bar), beads loaded
with biotinylated insulin (white bar), and beads loaded with biotiny-
lated calreticulin (hatched bar) are shown.
ERp57-Calreticulin Complex Formation18862
 at K
U
 Leuven U
niversity Library on M
arch 24, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
was generated to order by Eurogentec (Seraing, Belgium), whereas the
anti-calreticulin serum was obtained from Cambridge Bioscience (Cam-
bridge, UK). Purified, recombinant PDI was a gift from Professor N.
Bulleid, University of Manchester, UK.
ERp57 and PDI Derivatives—Wild type human ERp57 and human
PDI were as previously described (7). PDI/ERp57 chimeric constructs
2–6 (cf. Ref. 19) were removed from the pVL1392 vector by restriction
digestion and then ligated into either pBluescript KS II or pBluescript
SK II under the control of the T7 promoter (cf. Ref. 7). The ERp57ss
construct was generated by using PCR to remove the region encoding
the signal sequence and to introduce an ATG start codon immediately
before that encoding the first residue of the mature sequence. The
precise origin of each ERp57/PDI chimera is indicated in the legend to
Fig. 1. The thirteen ERp57 b domain point mutants (V267A, V267W,
Y269A, Y269W, E270A, K274A, R280A, N281A, V283A, V283L,
V283W, F299A, and F299W) were generated by mutagenesis of the wild
type coding region present in pBluescript KS II, and all mutants were
authenticated by DNA sequencing.
Cross-linking Analysis—The ability of wild type ERp57, and the
various b domain point mutants, to associate with the endogenous
calreticulin present in ER-derived canine pancreatic microsomes was
carried out essentially as previously described (7). A flexi rabbit reticu-
locyte lysate system was used to synthesize the polypeptides at 30 °C
for 1 h, and translation was terminated by treatment with 2 mM puro-
mycin. Cross-linking with BMH (final concentration, 500 M) and prod-
uct identification by immunoprecipitation were also as previously
detailed (7).
Preparation of Biotinylated Calreticulin—A calreticulin cDNA frag-
ment lacking the ER signal sequence was amplified by PCR from a
plasmid containing the full-length cDNA (20) utilizing a modified sense
primer incorporating an NruI site at its 5 end to facilitate its cloning
downstream of the biotin purification tag present in the Pin-Point Xa-1
vector (Promega). Sequencing of the recombinant Pin Point construct
confirmed that the mature calreticulin coding region was inserted ad-
jacent to, and in frame with, the plasmid fusion tag with an intact factor
Xa cleavage site. E. coli strain JM109 harboring the expression plasmid
was grown to an optical density of 0.4–0.6 in media supplemented with
2 mM biotin, and expression of the fusion protein was induced with 100
M isopropyl-1-thio--D-galactopyranoside for 2 h. Cells were har-
vested, lysed in the presence of a protease inhibitor mixture (Sigma),
and the resulting cell lysate passed over a SoftLink avidin resin as
described by the manufacturers (Promega). Biotin-tagged recombinant
protein was eluted with buffer containing a gradient of 5 to 20 mM
Biotin and exchanged into 20 mM HEPES, pH 7.5, 1 mM EDTA, 50 mM
NaCl by dialysis. Samples were tested by Western blotting using
streptavidin-coupled horseradish peroxidase, and fractions containing
the majority of the biotin-tagged calreticulin were pooled. The final
concentration of biotin-tagged calreticulin was determined using the
DC Bio-Rad Protein Assay (Bio-Rad, Hemel Hempsted, UK).
Expression and Purification of His-tagged Proteins—A version of
calreticulin lacking its ER signal sequence, and with an N-terminal
10 His tag, was generated in the vector pET16b and incorporated a
factor Xa cleavage site between the poly-His tag and the calreticulin
polypeptide. The recombinant protein was expressed in the Escherichia
coli origami (DE3) strain (Novagen, Nottingham, UK) and purified
under native conditions as recommended by the manufacturer (Invitro-
gen, Paisely, UK). Mature, wild type ERp57 was cloned into a modified
version of pET23b, which encodes for the sequence MHHHHHHM,
prior to the first amino acid of the mature sequence (21), and selected
point mutants generated in this construct were expressed in E. coli
strain BL21(DE3)pLysS grown either in LB media or in M9 minimal
media at 37 °C, 200 rpm and induced at an A600 of 0.3 for 3 h with 1 mM
isopropyl -D-thiogalactoside. Cell lysis and protein purification were
carried out as per the purification of ERp18 (22). The concentration of
each protein was determined spectrophotometrically using a calculated
FIG. 3. Binding of ERp57 derivatives to immobilized calreticu-
lin. ERp57 (A), ERp57 C (B), and chimeras 2–6 (C–G) were synthe-
sized as 35S-labeled polypeptides in reticulocyte lysate and analyzed for
binding to immobilized calreticulin as described in the legend to Fig. 2.
Levels of radiolabeled material that are significantly above background
are indicated by a gray arrowhead (cf. H). In some cases, the assay was
carried out two (chimera 6) or four times (PDI, ERp57, ERp57C, and
chimeras 3 and 4), and a summary of these data are presented in panel
H. Where appropriate, the average value and standard error for the
proportion of material recovered with beads alone (checkerboard bar),
beads loaded with biotinylated insulin (white bar), and beads loaded
with biotinylated calreticulin (hatched bar) are shown. Calreticulin
binding of an ERp57 derivative that is different from that of the wild
type protein to a significance of 0.01 is shown by a double asterisk.
There is no significant difference between the values obtained for
ERp57C and chimera 3.
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absorption coefficient of 45,200 M1 cm1 (molecular weight of 55,276)
for the wild type protein.
ERp57 Pull-down Assay—UltraLink NeutrAvidin beads (Pierce)
were preincubated with 20% bovine serum albumin to block any non-
specific binding sites and washed 5 times in TBS (50 mM Tris-HCl, pH
7.5, 150 mM NaCl). In some cases, biotin-tagged calreticulin (5 g), or
an equimolar amount of biotin-tagged insulin (0.6 g), was then
immobilized on these beads by mixing overnight at 4 °C in the presence
of 100 M phenylmethylsulfonyl fluoride and 0.25% TX-100 in TBS.
Control reactions also included a 10-fold molar excess of “native” or
“scrambled” RNase A (1.4 g), during the overnight incubation. The
beads were recovered by centrifugation for 2 min at 3,000 rpm in a
microcentrifuge and washed three times in 0.25% TX-100 in TBS. 10 l
of a specific in vitro translation reaction, carried out in the absence of
canine pancreatic microsomes and pre-spun at 1000  g for 2 min, was
then mixed with 20 l of NeutrAvidin beads alone, 20 l of NeutrAvidin
beads loaded with biotin-tagged insulin, or 20 l of NeutrAvidin beads
loaded with biotin-tagged calreticulin. Competition experiments were
performed together with a 10-fold molar excess of His-tagged calreticu-
lin (25 g) or recombinant PDI (30 g). 50 l of TBS with 0.25% (v/v)
TX-100 was added to each sample, they were mixed at room tempera-
ture for 2 h, and the beads were then recovered by centrifugation,
washed four times in TBS with 0.25% (v/v) TX-100, and then once with
TBS.
SDS-PAGE Analysis—Samples were denatured and solubilized in
SDS sample buffer by heating to 70 °C for 10 min before being resolved
on SDS-PAGE gels of 8% (cross-linking products) or 15% (pull-down
assays) acrylamide. Gels were fixed, exposed to a phosphorimaging
plate, and visualized on a Fuji BAS-1800 bioimaging system. Quantifi-
cation was carried out using AIDA software supplied by Raytek Scien-
tific Ltd. (Sheffield, UK). Where shown, statistical significance was
determined by using a two-tailed Student’s t test (Microsoft Excel).
Biophysical Analysis—Far-UV circular dichroism spectra were re-
corded on a Jasco J600 spectrophotometer. All spectra were collected at
25 °C as an average of 8 scans, using a cell with a path length of 0.1 cm,
scan speed of 20 nm/min, a spectral bandwidth of 1.0 nm, and a time
constant of 1 s. The maximal high tension voltage was 750 V. All spectra
were corrected for the blank spectra with no protein added.
RESULTS
Although ERp57 and PDI share significant sequence identity
and most likely have similar tertiary structures (13), we have
previously shown that ERp57 forms stable complexes with
calnexin and calreticulin, whereas PDI does not (7). In this
study we have exploited a series of chimeras of PDI and ERp57
(19), together with other ERp57 derivatives and point mutants,
to define the domains of ERp57 that are required for its specific
association with the ER lectins calreticulin and calnexin.
Only a Subset of ERp57 Derivatives Bind to Calreticulin in
an in Vitro Pull-down Assay—Our previous studies of ERp57
binding to ER lectins relied on a cross-linking assay (7) that
may be influenced by differences in the number and location of
the cysteine residues present in the various chimeras (see Fig.
1). Furthermore, such assays are unable to formally distin-
guish binding from close proximity. We therefore established a
quantitative “pull-down” assay that reflected authentic binding
between two components to investigate the association be-
tween ERp57 and the ER lectin calreticulin. Recombinant cal-
reticulin, containing an N-terminal biotinylated tag, was im-
mobilized on tetrameric NeutrAvidin-coated beads and used as
a ligand for 35S-labeled ERp57 and its derivatives that were
generated by in vitro translation. When wild type ERp57 was
FIG. 4. Alignment of the region between the b and a domains of human PDI and ERp57. Identical residues are highlighted in black,
numbering is for the full-length proteins. All gaps in the PDI alignment lie between secondary structural elements in the published model of the
b domain (18). Asterisks above the alignment indicate sites of mutations reported to effect PDI substrate binding (18); asterisks below the alignment
indicate sites of mutations made in this study in ERp57. The locations of Ile289 in PDI and Phe299 in ERp57 are also indicated by arrowheads.
FIG. 5. Cross-linking of wild type ERp57 and b domain point
mutants to the endogenous calreticulin present in canine pan-
creatic microsomes. mRNAs encoding wild type (A) or various point
mutants of ERp57 (B–D) were translated in a rabbit reticulocyte lysate
translation system in the presence of canine pancreatic microsomes,
treated with BMH, and analyzed by immunoprecipitation. In this case
total products after cross-linking, products immunoprecipitated by the
anti-ERp57 serum with and without cross-linking, and products immu-
noprecipitated with anti-calreticulin after cross-linking were analyzed.
ERp57 polypeptides are indicated by a black arrow, whereas adducts
with calreticulin are denoted by a brace. The efficiency of cross-linking
for each ERp57 derivative to calreticulin was estimated using phospho-
rimaging. The total amount of radiolabeled material present in the
anti-calreticulin immunoprecipitation (lane 4) was quantified and ex-
pressed as a percentage of the total radiolabeled ERp57 recovered in the
anti-ERp57 immunoprecipitation without BMH treatment (lane 2).
Representative examples of different ERp57 bmutants are shown, and
the quantification results for all of the mutants analyzed are shown in
Table I.
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incubated with immobilized calreticulin, a little over one-third
of the radiolabeled protein was specifically recovered with the
beads (Fig. 2A, cf. lanes 1 and 4, Fig. 2D). In contrast, only
background levels of binding (3–5%) were found when beads
alone or beads loaded with biotinylated insulin were used (Fig.
2A, cf. lanes 1–3, see also Fig. 2D).
Preincubation of the calreticulin bait with a 10-fold molar
excess of scrambled or native RNase A caused either a minor
reduction in binding (to 30%; cf. 37%) or had no significant
effect (38%; cf. 37%), respectively (Fig. 2A, cf. lanes 4–6, Fig.
2D). Thus, ERp57 binding to immobilized calreticulin bears the
hallmark of complex formation rather than the binding of a
potentially misfolded protein (ERp57) to a candidate molecular
chaperone (calreticulin). As expected, a 10-fold molar excess of
soluble recombinant His-tagged calreticulin efficiently com-
peted with the immobilized biotinylated calreticulin for ERp57
binding, whereas a similar molar excess of recombinant His-
tagged PDI did not (Fig. 2A, lane 7, 5%; lane 8, 30%). Our
previous cross-linking analysis indicated that the presence of
an uncleaved signal sequence at the N terminus of ERp57 did
not affect its ability to bind to calreticulin (7). We confirmed
that this was the case by analyzing an ERp57 derivative lack-
ing its N-terminal signal sequence (ERp57ss) in the pull-
down assay and finding that ERp57-calreticulin complex for-
mation was essentially unaffected (Fig. 2, cf. A, B, and D). The
specificity of the interaction between radiolabeled ERp57 and
immobilized, biotinylated calreticulin was further underscored
by the observation that only 2% of radiolabeled PDI was
recovered in this pull-down assay under any of the various
conditions tested (Fig. 2, C and D).
Having established a robust pull-down assay, various ERp57
chimeras were investigated. Radiolabeled versions of ERp57C
and five chimeras (see Fig. 1, constructs 2–6) were synthesized
in vitro and analyzed using the pull-down assay outlined above.
As before, a substantial fraction of ERp57 (37%) was bound to
beads loaded with biotin-tagged calreticulin but not to control
beads (cf. Fig. 3A, lanes 2–4, Fig. 3H). When the ERp57C
polypeptide and the various ERp57/PDI chimeras were tested
using the pull-down assay, it was immediately apparent that
only a subset of these proteins displayed significant binding to
the immobilized calreticulin (Figs. 3, B–H). Hence, although
ERp57C and chimeras 3 and 4 showed levels of specific bind-
ing substantially above the levels observed in matched controls
(Fig. 3, B, D, E, and H), no such binding was detected with
constructs 2, 5, or 6 (Fig. 3, C, F, G, and H).
Quantification of the pull-down data (see Fig. 3H) showed
that, although wild type ERp57, ERp57C, and chimeras 3 and
4 all showed significant levels of binding to calreticulin, there
was a clear and statistically significant difference in the effi-
ciency of binding between the various constructs. Thus, only
chimera 4 showed binding equivalent to wild type ERp57 (40
and 37% respectively, see Fig. 3H), whereas the binding of
both ERp57C and chimera 3 were both significantly reduced
(19 and 23% respectively, see Fig. 3H). Thus, the b and b
domains of ERp57 are the minimal elements necessary for
calreticulin binding that are defined by this analysis (cf. Fig. 1).
Furthermore, although the presence of the C-terminal region is
not absolutely required for complex formation, it is required for
levels of binding akin to that seen with the wild type protein.
Generation of ERp57 b Domain Point Mutants and Their
Analysis by Cross-linking—The b domain of PDI has been
shown to play a major role in the binding of peptide substrates
(16–18), and the b domains of ERp57 and PDI show substan-
tial sequence divergence from one another (24% sequence iden-
tity, see Fig. 4; cf. 49% for the a domains, see Ref. 23). Our
analysis of the ERp57/PDI chimeras indicated that the princi-
pal calreticulin binding site was located somewhere in its b and
b domains, and we hypothesized that the b domain of ERp57
might make a major contribution to the calreticulin binding
site analogous to the role of the PDI b domain in substrate
binding. To investigate this possibility further, a number of
targeted point mutations based on residues important for sub-
strate binding to PDI (18) were introduced into the b domain of
ERp57. The mutations were selected based on the alignment of
the b domains from ERp57 and PDI (see Fig. 4) and the
recently reported identification of the primary substrate bind-
ing site within the b domain of human PDI (18). In particular,
several mutations were made in the four residues (Val267,
Tyr269, Val283, and Phe299) analogous to those found to define
the binding site in PDI, whereas single mutations to alanine
were made in residues analogous to those juxtaposed to this
site (Glu270, Lys274, Arg280, and Asn281).
The ability of the various ERp57 b domain mutants to as-
sociate with calreticulin was initially screened using a previ-
ously established cross-linking assay (7). In all cases the ERp57
point mutants were efficiently synthesized and imported into
microsomes (Fig. 5, A–D, data not shown). For most of the point
mutants, some BMH-dependent cross-linking products were
visible, although the intensity of these adducts was variable
(e.g. Fig. 5, A–D, data not shown, see also Table I). Immuno-
precipitation confirmed that most, although not all, of the point
mutants formed distinct adducts with calreticulin (Fig. 5, A–D,
lane 4; and data not shown). Where visible, multiple ERp57/
calreticulin adducts were observed as previously described for
the wild type protein (7). These multiple products most likely
reflect cross-linking between different cysteine residues pres-
ent within ERp57 and calreticulin (7). To compare the effi-
ciency of cross-linking for the different b point mutants, the
relative proportion of ERp57 cross-linked to calreticulin was
determined for each of the mutants and expressed as a per-
centage of the value obtained with the wild type protein (see
Table I). This quantitative analysis suggested that there was a
significant variation in the efficiency of cross-linking of the
ERp57 point mutants to calreticulin, with the F299W mutant
generating no clearly discernable adducts (see Fig. 5D, lane 4,
and Table I). We conclude that specific residues in the b
domain of ERp57 (Arg280, Val283, and Phe299) are important for
its ability to be cross-linked to calreticulin efficiently.
Pull-down Analysis of ERp57 b Domain Point Mutants—
Because the majority of the ERp57 b domain point mutants
TABLE I
Percentage of ERp57 b domain point mutants found cross-linked to
endogenous calreticulin
ERp57 b domain mutant WTa
%
Wild type 100
Val267 3 Ala 83
Val267 3 Trp 83
Tyr269 3 Ala 100
Tyr269 3 Trp 83
Glu270 3 Ala 100
Lys274 3 Ala 83
Arg280 3 Ala 33
Asn281 3 Ala 83
Val283 3 Ala 67
Val283 3 Leu 33
Val283 3 Trp 67
Phe299 3 Ala 33
Phe299 3 Trp 17
a The fraction of the membrane-associated ERp57 derivative that was
cross-linked to the endogenous calreticulin present in canine pancreatic
microsomes was established by quantitative phosphorimaging (see also
Fig. 5). These values were then expressed as a percentage of that found
with the wild type protein (%WT).
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FIG. 6. The binding of ERp57 b domain point mutants to immobilized calreticulin. ERp57 (A) and point mutants 5-Glu270 3 Ala (B)
10-Val283 3 Leu (C), and 13-Phe299 3 Trp (D) were synthesized as 35S-labeled polypeptides in reticulocyte lysate and analyzed for binding to
immobilized calreticulin as described in the legend to Fig. 2. The radiolabeled ERp57 that was recovered with the calreticulin-loaded beads is
indicated by a gray arrowhead. All of the point mutants listed in Table I were analyzed in this way, and a representative set of mutants is
presented. For each ERp57 b mutant the assay was repeated three times, and the average value and standard error for the proportion of material
recovered with beads alone (checkerboard bar), beads loaded with biotinylated insulin (white bar), and beads loaded with biotinylated calreticulin
(hatched bar) are shown in panel E. Calreticulin binding of an ERp57 b domain mutant that is different from that of the wild type protein to a
significance of 0.01 is shown by a double asterisk.
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displayed an ability to be cross-linked to the endogenous cal-
reticulin present in ER-derived microsomes (Table I), the thir-
teen point mutants were all analyzed for calreticulin binding
using the pull-down assay (Fig. 6, A–E, data not shown). Sig-
nificantly, the analysis of the b mutants using the pull-down
assay revealed that almost all of the point mutants had a
severe defect in calreticulin binding (Fig. 6E). Quantification
showed that only one of the thirteen point mutants analyzed,
ERp57-Glu270 3 Ala, bound to immobilized calreticulin with
an efficiency similar to the wild type protein (35 and 37%,
respectively, Fig. 6, A, B, and E). A second mutant, Val283 3
Ala, exhibited an intermediate level of binding (20%, Fig. 6E),
whereas three other mutants, Val2673 Ala, Tyr2693 Trp, and
Val283 3 Leu (see Fig. 6C), all showed levels of binding that
were significantly above their matched controls but substan-
tially reduced in comparison to the wild type protein (12,
15, and12%, respectively, see Fig. 6E). All of the other point
mutants displayed levels of binding that were not significantly
above the background level (Fig. 6, D and E). Taken together,
the pull-down analysis of the b domain point mutants is con-
sistent with a model where this region of ERp57 plays a pivotal
role in its stable association with the ER lectin calreticulin.
The mutations that were introduced into the ERp57 b do-
main were based upon previous studies of PDI where compa-
rable alterations had been shown to cause minimal perturba-
tion to the structure of the protein. To investigate this issue
further for ERp57, we purified two of the mutants with a strong
defect in calreticulin binding, the Phe299 3 Ala and Phe299 3
Trp mutants, and analyzed them using CD spectroscopy. Both
mutants showed near-identical CD spectra with the wild type
protein (Fig. 7A), indicating that there were no gross changes
in their respective structures.
DISCUSSION
During the course of this study we have investigated the
molecular basis for the specific interaction between the PDI-
like protein ERp57 and the soluble ER lectin calreticulin.
ERp57/PDI chimeras and ERp57 b domain point mutants
were synthesized in vitro, and their binding to endogenous ER
lectins and recombinant calreticulin was determined. Chime-
ras 2–6 (cf. Fig. 1) have previously been used to study collagen
prolyl 4-hydroxylase complex formation, where PDI functions
as the  subunit (19). This study indicated that the chimeras
could attain a native-like conformation and, in the cases of
ERp57aPDIbbac and ERp57abPDIbac, form active collagen
prolyl 4-hydroxylase complexes (19).
Pull-down Analysis Maps the Calreticulin Binding Site to
within the b and b Domains of ERp57—Previous studies indi-
cated that ERp57 could bind to calreticulin in solution (7, 24)
and showed this interaction was crucial for ERp57 function (5).
The estimated dissociation constant for the complex (9.1 
3.0)  106 M (11) suggested that binding may be strong
enough to survive a pull-down assay, and we found that this
was the case. Hence, a substantial proportion of wild type
ERp57 was specifically recovered bound to immobilized calre-
ticulin, whereas no specific binding of PDI was observed in the
same assay. Likewise, the binding of radiolabeled ERp57 to the
immobilized calreticulin bait could be prevented by an excess of
soluble calreticulin but not of PDI. Previous studies indicate
that calnexin and calreticulin can bind non-glycosylated pro-
teins both in vitro and in vivo (3, 4, 25), perhaps reflecting a
role as chaperones that is additional to their lectin function.
However, when either scrambled or native RNase A was incor-
porated into our pull-down assay, neither of these polypeptides
competed efficiently with ERp57 for binding to immobilized
calreticulin (cf. Ref. 16). We conclude that the binding of ERp57
to immobilized calreticulin reflects the formation of a biologi-
cally relevant complex and not the binding of a population of
misfolded ERp57 polypeptides to calreticulin acting as a broad
specificity chaperone.
When ERp57 derivatives were tested in the pull-down assay,
only ERp57C missing the C-terminal extension (c) and chi-
meric constructs ERp57abbPDIac and PDIaERp57bbac
bound calreticulin at significant levels. The quantitative na-
ture of the assay revealed clear differences in binding, and only
PDIaERp57bbac displayed binding equivalent to wild type
ERp57. Hence, the a domain of ERp57 appears to be entirely
dispensable for its binding to calreticulin (cf. Fig. 1). This
conclusion is consistent with previous studies of the assembly
of archetypal PDI into a functional collagen prolyl 4-hydroxy-
lase complex, where the loss or replacement of its a domain had
the least impact upon the activity of the complex (19). The
deletion of the C-terminal region alone (ERp57C) has the
same effect as the substitution of the C-terminal region and the
a domain together (chimera 3), with both derivatives binding
roughly half as well as the wild type protein (cf. Fig. 3H). We
conclude that it is the lack of the C-terminal region in these two
derivatives that causes the reduction in binding we observe and
that the a domain of ERp57 plays no direct role in calreticulin
binding. A specialized role for the C-terminal region of ERp57
in calreticulin binding is consistent with its distinct nature
(basic) as compared with the more acidic C-terminal region of
PDI (26).
Most ERp57 b Domain Point Mutants Are Severely Compro-
mised in Calreticulin Binding—A striking result of our pull-
down analysis was that only two of the 13 mutants displayed
calreticulin binding levels anywhere near that of the wild type
FIG. 7. Further analysis of ERp57 b domain mutants. A, far-UV
CD spectra of wild type ERp57 (black line), Phe2993 Ala (red line), and
Phe299 3 Trp (blue line) mutants of ERp57. B, space-filling models
illustrating the substrate binding site in human PDI, numbering is for
the full-length protein (modified from Ref. 18). Residues whose muta-
tion caused a major decrease in peptide binding are highlighted in green
with residue Ile289 specifically picked out in magenta, residues whose
mutation have a minor effect on substrate binding are in yellow, the
residue whose mutation had no effect on substrate binding is in blue.
Proline 262 whose mutation resulted in the production of no full-length
PDI is in cyan (18). C, residues of human PDI that, when the analogous
residues are mutated in ERp57 (cf. Fig. 4), have an effect on calreticulin
binding. The coloration is as described for panel B.
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protein, namely Glu270 3 Ala and Val283 3 Ala. CD spectros-
copy showed that mutants Phe299 3 Ala and Phe299 3 Trp
assumed a native-like structure, and hence their defective cal-
reticulin binding is not a consequence of their gross misfolding.
For most of the ERp57 bmutants, no significant binding above
the level of the background signal was detected, independent of
their capacity to form cross-linking products with calreticulin.
This distinction may reflect the more rigorous nature of the
pull-down assay.
A comparison of the effects of mutations on substrate binding
by PDI (cf. Ref. 18) with the effects of mutations on ERp57-
calreticulin interactions is shown in Fig. 7 (B and C). Signifi-
cantly, all residues whose mutation disrupts PDI-substrate
binding also have an effect on ERp57-calreticulin interactions.
In both cases, the greatest perturbation is observed after mu-
tation of the equivalent residue within the b domain, namely
Ile289 in PDI and Phe299 in ERp57. This strongly suggests that
the generalized substrate binding site located in the b domain
of PDI has become specialized in ERp57 for a specific interac-
tion with calreticulin and calnexin. However, although the
substrate binding site in PDI appears to be primarily defined
by four hydrophobic residues (18), the calreticulin interaction
site of ERp57 seems to encompass a larger region on the face of
the b domain (compare magenta and green residues in Fig. 7, B
and C). Although different assays are used to monitor the
respective interactions, this most likely reflects authentic dif-
ferences in the association of different PDI family members
with their binding partners.
The binding sites of PDI and PDIp are both relatively small
(18, 27), and the binding of both proteins to model peptides is
inhibited by low molecular weight compounds such as 2-propyl-
phenol and 4-propylphenol. In contrast, the binding of ERp57
to the P domain of calreticulin causes a chemical shift or
significant decrease in cross-peak intensity in the NMR spectra
FIG. 8. Conserved elements in calreticulin and ERp57. A, an alignment of the region of the P domain of calreticulin that interacts with
ERp57 (11) from human, mouse, C. elegans, and Drosophila. Identical residues are highlighted in black; numbering is for the full-length protein,
including the signal sequence. B, alignment of the b domains of ERp57 from human, mouse, C. elegans, and Drosophila (based on boundaries
defined in Ref. 21). Identical residues are highlighted in black; numbering is for the full-length protein. Residues whose mutation effects human
ERp57-calreticulin interactions are indicated by an asterisk below the sequence, Glu270 whose mutation does not affect these interactions is
indicated by the symbol “:” below the sequence.
FIG. 9. A comparison of substrate binding to PDI and ERp57.
Models indicating the regions of PDI and ERp57 that interact with
large substrates and calreticulin respectively are shown. High resolu-
tion structures of domains of calnexin (10) and calreticulin (8) suggest
that ERp57 binds to the conserved P-loop of these two lectins, and NMR
studies confirm this model (11). We propose that ERp57 shows an
indirect interaction with its substrate via its interaction with calreti-
culin, where the b domain of ERp57 is an essential element of the
calreticulin binding site. Our data indicate that the C-terminal exten-
sion of ERp57 enhances calreticulin binding significantly, and this is
reflected in our working model. In comparison, PDI shows a direct
interaction with its substrate, principally through its b domain, al-
though the a and a domains contribute to the binding of larger sub-
strates (16, 17).
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for 21 of the residues between Ile225 and Asn251 at the tip of the
P domain (11), indicating a more substantial binding site than
that of PDI or PDIp. The tip of the P domain is highly conserved
between the human, mouse, Caenorhabditis elegans, and Dro-
sophila proteins (Fig. 8A), suggesting a similar degree of con-
servation may be apparent in its binding partner. Inspection of
the b domains of ERp57 from the same species reveals that
31% of the residues are conserved (Fig. 8B). Of particular note
are residues Tyr264-Ala287 (71% identity in 24 amino acids),
which overlap the region primarily involved in substrate bind-
ing to ERp57 (this study) and its equivalent in PDI (18). Sig-
nificantly, all of the residues in the b domain where mutation
perturbs calreticulin binding lie within this region and are
conserved, while the single residue within this region where
mutation did not affect the interaction (Glu270 3 Ala) is not
conserved. Taken together, these data support a model where
the tip of the calreticulin P domain binds to a conserved feature
located within the b domain of ERp57.
Although our study has focused upon the soluble ER lectin,
calreticulin, structural studies (8, 9, 11, 28) suggest that in
practice our model is likely to depict the molecular basis for the
interaction of both calreticulin and calnexin with ERp57.
Taken together, our results indicate that ERp57 can be viewed
as a specialized version of PDI that binds specifically to two
related ER lectins, calnexin and calreticulin, in place of the
broad range of substrates that can associate with PDI (cf. Fig.
9). These ER lectins would then act to specifically recruit ap-
propriately glucose-trimmed glycoprotein substrates (see Ref.
1) to bind to the complex where they could be acted upon by
ERp57 (cf. Fig. 9).
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